adeno-associated virus gene therapy (University of Massachusetts/University of Florida/NHLBI)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameadeno-associated virus gene therapy (University of Massachusetts/University of Florida/NHLBI)
Drug Alias NamerAAV2-CB-hAATAAV gene therapy (University of Massachusetts/University of Florida/NHLBI)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionAlpha-1-antiproteinase stimulants
TargetsAlpha-1-antiproteinase
Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity of Massachusetts
China Registration ClassN/A

Develop Information

Active CompaniesNational Heart, Lung And Blood InstituteUniversity Of FloridaUniversity of Massachusetts
Inactive CompaniesN/A
Active Indicationsalpha 1-Antitrypsin Deficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A